Annelies De Clercq
European Patent Attorney
De Clercq & Partners
Sint-Martens-Latem, Belgium
I am a European Patent Attorney working in various fields of technology including life sciences and chemistry and specifically biotechnology.
My organisation
Professional Services & Consulting
Sint-Martens-Latem, Belgium
About me
Annelies De Clercq holds a Master of Biochemistry and a PhD in Biotechnology under supervision of Prof. Dr. Dirk Inzé (University of Ghent, Belgium, Department of Plant Systems Biology, Flanders Institute for Biotechnology, VIB).
Prior to joining De Clercq & Partners in 2010, Annelies worked for almost three years as a postdoctoral researcher in Molecular and Cellular Biology focusing on cancer immunotherapy under Prof. Dr. Aristides Eliopoulos (Medical School, University of Crete, Greece).
In July 2014, she qualified as a European Patent Attorney. In 2023, she successfully obtained the Diploma on Patent Litigation in Europe from the University of Strasbourg (France), qualified as a European Patent Litigator, and registered as a representative before the Unified Patent Court (UPC).
Annelies has knowledge and expertise in various fields of technology including life sciences and chemistry and more specifically biochemistry, biotechnology, molecular biology, cell biology, and food and feed technology.
Annelies’ areas of practice include drafting and prosecution of European, PCT, and national patent applications, oppositions and appeal proceedings before the European Patent Office, opinions regarding patentability, freedom-to-operate, infringement and validity of intellectual property rights, and general and strategic advice in intellectual property matters.
My organisation
Skills
- Intellectual property
- Patents and trademarks
- life sciences
Additional questions
How would you categorise yourself?
Organisation Type
Areas of expertise
Therapeutic areas
1. I accept the General Terms & Conditions and Privacy Statement, available on flandersvaccine.be and agree that pictures can be taken at the event and be used for Flanders Vaccine communication purposes.
I agree